Literature DB >> 15833477

Palliative therapy for pancreatic/biliary cancer.

Michael G House1, Michael A Choti.   

Abstract

Palliative treatment for unresectable periampullary cancer is directed at three major symptoms: obstructive jaundice, duodenal obstruction, and cancer-related pain. In most cases, the pattern of symptoms at the time of diagnosis in the context of the patient's medical condition and projected survival influence the decision to perform an operative versus a non operative palliative procedure. Despite improvements in preoperative imaging and laparoscopic staging of patients with periampullary cancer and hilar cholangiocarcinoma, surgical exploration is the only modality that can definitively rule out resectability and the potential for curative resection in some patients with nonmetastatic cancer. Furthermore, only surgical management achieves successful palliation of obstructive symptoms and cancer-related pain as a single procedure during exploration. To take advantage of the long-term advantages afforded by surgical palliation,operative procedures must be performed with acceptable morbidity. The average postoperative length of hospital stay for patients who undergo surgical palliation is less than 15 days, even in those who develop minor complications. The average survival of patients who receive surgical palliation alone for nonmetastatic, unresectable pancreatic cancer is approximately 8 months. As with all treatment planning, palliative therapy for pancreatic and biliary cancer should be planned using a multidisciplinary approach, including input from the surgeon, gastroenterologist, radiologist,and medical and radiation oncologist. In this way, quality of life can be optimized in most patients with these diseases.

Entities:  

Mesh:

Year:  2005        PMID: 15833477     DOI: 10.1016/j.suc.2005.01.022

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  10 in total

1.  Pancreatic adenocarcinoma.

Authors:  Margaret A Tempero; J Pablo Arnoletti; Stephen Behrman; Edgar Ben-Josef; Al B Benson; Jordan D Berlin; John L Cameron; Ephraim S Casper; Steven J Cohen; Michelle Duff; Joshua D I Ellenhorn; William G Hawkins; John P Hoffman; Boris W Kuvshinoff; Mokenge P Malafa; Peter Muscarella; Eric K Nakakura; Aaron R Sasson; Sarah P Thayer; Douglas S Tyler; Robert S Warren; Samuel Whiting; Christopher Willett; Robert A Wolff
Journal:  J Natl Compr Canc Netw       Date:  2010-09       Impact factor: 11.908

Review 2.  [Palliative bypass surgery].

Authors:  A Wojtyczka; T Moesta; C Kuntz; T Lehnert
Journal:  Chirurg       Date:  2006-03       Impact factor: 0.955

Review 3.  Palliative Care for Pancreatic and Periampullary Cancer.

Authors:  Jennifer A Perone; Taylor S Riall; Kelly Olino
Journal:  Surg Clin North Am       Date:  2016-12       Impact factor: 2.741

4.  Operative procedures for unresectable pancreatic cancer: does operative bypass decrease requirements for postoperative procedures and in-hospital days?

Authors:  John M Lyons; Ami Karkar; Camilo C Correa-Gallego; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; T Peter Kingham; William R Jarnagin; Murray F Brennan; Peter J Allen
Journal:  HPB (Oxford)       Date:  2012-05-15       Impact factor: 3.647

Review 5.  TTD consensus document on the diagnosis and management of exocrine pancreatic cancer.

Authors:  M Benavides; A Abad; I Ales; A Carrato; E Díaz Rubio; J Gallego; J García-Foncillas; C Grávalos; B Laquente; C Pericay; F Rivera; J Tabernero; E Aranda
Journal:  Clin Transl Oncol       Date:  2014-04-12       Impact factor: 3.405

6.  Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors.

Authors:  Jacek A Smigielski; Lukasz Piskorz; Marcin Wawrzycki; Przemysław Dobielski; Małgorzata Pikala; Sławomir Jabłoński; Marian Brocki
Journal:  Arch Med Sci       Date:  2013-08-08       Impact factor: 3.318

7.  Hepaticocholecystoenterostomy as an alternative to hepaticojejunostomy for biliary bypass.

Authors:  J Gani; K Lewis
Journal:  Ann R Coll Surg Engl       Date:  2012-10       Impact factor: 1.891

8.  Validation of administrative hospital data for identifying incident pancreatic and periampullary cancer cases: a population-based study using linked cancer registry and administrative hospital data in New South Wales, Australia.

Authors:  Nicola Creighton; Richard Walton; David Roder; Sanchia Aranda; David Currow
Journal:  BMJ Open       Date:  2016-07-01       Impact factor: 2.692

9.  Therapeutic EUS: Biliary drainage - The interventional radiologist's perspective.

Authors:  Francesco De Cobelli; Paolo Marra; Pietro Diana; Giorgio Brembilla; Massimo Venturini
Journal:  Endosc Ultrasound       Date:  2017-12       Impact factor: 5.628

10.  Efficacy and safety of chemotherapy after endoscopic double stenting for malignant duodenal and biliary obstructions in patients with advanced pancreatic cancer: a single-institution retrospective analysis.

Authors:  Kazuyuki Matsumoto; Hironari Kato; Shigeru Horiguchi; Koichiro Tsutsumi; Yosuke Saragai; Saimon Takada; Sho Mizukawa; Shinichiro Muro; Daisuke Uchida; Takeshi Tomoda; Hiroyuki Okada
Journal:  BMC Gastroenterol       Date:  2018-10-26       Impact factor: 3.067

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.